Prostate MRI AI
AI-assisted prostate MRI segmentation, alignment, and reporting designed to save time on every case.
Key Features
Series Auto-Detection
Automatically identifies and populates biparametric series (T2, ADC, High B-value DWI) from any scanner vendor.
AI Segmentation
Automated whole prostate gland contouring with full manual editing tools. Robust to motion artifacts.
Lesion Annotation
Physician-directed tools for marking and contouring regions of interest across aligned sequences.
Fusion Biopsy Export
Direct export to Navigo and other MRI/US fusion biopsy systems via native ROI and DICOM RTSTRUCT formats.
PSA Density
Automatic prostate volume measurement from segmentation, combined with the entered PSA value to calculate PSA density.
Auto-Windowing
Optimizes visualization based on published best practices for biparametric MRI.
The Problem
Prostate cancer is the second most common cancer in men worldwide, with 1.4 million new cases diagnosed annually. MRI has become the standard of care in the diagnostic pathway, but reading prostate MRI is time-intensive: series selection, windowing, contouring, and measurement are all manual steps that vary between readers. Incumbent software solutions require expensive licenses and on-premise hardware. We want to change that.
Our Approach
Acurix Prostate AI is cloud-native — no local GPU hardware, no IT installation projects. Upload a study from any browser and receive AI-assisted contours in minutes.
The workflow is designed by a radiologist for radiologists. Series auto-detection eliminates manual series selection. Auto-windowing standardizes display. AI segmentation provides editable 3D contours, and the physician remains in control of every annotation and interpretation.
Volume and PSA Density
Prostate volume is measured automatically from the segmentation. Combined with the patient’s PSA value, the platform calculates PSA density — a measurement radiologists and urologists already use every day, computed consistently on every study.
Pricing
Contact us for pricing. Cloud-native architecture enables dramatically lower costs than incumbent solutions.
Acurix Prostate AI is under development and has not been cleared or approved by the U.S. Food and Drug Administration. It is not available for clinical use in the United States.